Education
About Us
Working with TipRanks
Follow Us
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
Total Valuation
Inhibikase Therapeutics has a market cap or net worth of $200.09M. The enterprise value is $87.89M.
Market Cap$200.09M
Enterprise Value$87.89M
Share Statistics
Inhibikase Therapeutics has 121,267,044 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding121,267,044
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Inhibikase Therapeutics’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -30.07%.
Return on Equity (ROE)-0.29
Return on Assets (ROA)-0.28
Return on Invested Capital (ROIC)-30.07%
Return on Capital Employed (ROCE)-0.30
Revenue Per Employee0.00
Profits Per Employee-1.83M
Employee Count15
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Inhibikase Therapeutics is ―. Inhibikase Therapeutics’s PEG ratio is 0.12.
PE Ratio―
PS Ratio0.00
PB Ratio2.38
Price to Fair Value2.38
Price to FCF-11.77
Price to Operating Cash Flow-5.06
PEG Ratio0.12
Income Statement
In the last 12 months, Inhibikase Therapeutics had revenue of 0.00 and earned -27.52M in profits. Earnings per share was -1.16.
Revenue0.00
Gross Profit-26.27K
Operating Income-28.59M
Pretax Income-27.52M
Net Income-27.52M
EBITDA-27.49M
Earnings Per Share (EPS)-1.16
Cash Flow
In the last 12 months, operating cash flow was -25.62M and capital expenditures 0.00, giving a free cash flow of -25.62M billion.
Operating Cash Flow-25.62M
Free Cash Flow-25.62M
Free Cash Flow per Share-0.21
Dividends & Yields
Inhibikase Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.65
52-Week Price Change-46.08%
50-Day Moving Average1.55
200-Day Moving Average1.79
Relative Strength Index (RSI)56.32
Average Volume (3m)132.72K
Important Dates
Inhibikase Therapeutics upcoming earnings date is Mar 26, 2026, After Close (Confirmed).
Last Earnings DateNov 14, 2025
Next Earnings DateMar 26, 2026
Ex-Dividend Date―
Financial Position
Inhibikase Therapeutics as a current ratio of 26.37, with Debt / Equity ratio of 0.00%
Current Ratio26.37
Quick Ratio26.37
Debt to Market Cap<0.01
Net Debt to EBITDA2.05
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Inhibikase Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Inhibikase Therapeutics EV to EBITDA ratio is -6.15, with an EV/FCF ratio of -8.83.
EV to Sales0.00
EV to EBITDA-6.15
EV to Free Cash Flow-8.83
EV to Operating Cash Flow-8.83
Balance Sheet
Inhibikase Therapeutics has $77.32M in cash and marketable securities with $0.00 in debt, giving a net cash position of $77.32M billion.
Cash & Marketable Securities$77.32M
Total Debt$0.00
Net Cash$77.32M
Net Cash Per Share$0.64
Tangible Book Value Per Share$1.37
Margins
Gross margin is -90.10%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-90.10%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Inhibikase Therapeutics is $6.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.25
Price Target Upside278.79% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast-100.00%
EPS Growth Forecast79.01%